Modern lifestyle has become a host for many abnormalities, especially with the gradual mutation, advancing maternal age and lack of proper healthcare infrastructure has depleted the live birth rate. Due to this, the priority of a number of governments in many countries is to take initiatives towards developing non-invasive solutions, launch a large number of screening programs and control the soaring level of genetic disorders with advanced technologies to meet the needs of the patients. Prenatal testing helps the expectant parent(s) in decision making, whether to continue or abort the pregnancy, as numerous cases related to Down syndrome, spina bifida, cleft palate, sickle cell anaemia, thalassemia, fragile X syndrome and Tay–Sachs disease among others have been reported, as a consequence of the mutant genes and an abnormal chromosomal structure.
The scope of prenatal screening market has widened because of its advantages and the increasing need of Assisted Reproductive Technologies(ART). The first non-invasive prenatal test, developed by Sequenom, was approved in 2010, which has fuelled the overall growth of the prenatal testing market. Non-invasive prenatal testing (NIPT) is an emerging technology which analyzes fetal cell-free DNA circulating in maternal blood to identify fetal chromosomal aneuploidies. Down syndrome, Edwards syndrome, Patau syndrome, and monosomy X are the most common chromosomal aneuploidies that occur in approximately 1 in 450 newborns across the world.
Recently developed non-invasive screening tests are rising in demands because of the emergence of advanced technologies such as next generation sequencing, high throughput screening, and cell free fetal DNA. The clinical application of these tests has risen exponentially in developed countries as compared to developing countries, although these tests are amply available in developing countries. The advent of NIPT is expected to eliminate the disadvantages associated with the screening methods such as low rate of accuracy with maternal serum screening and NT scan, and risk of miscarriage with invasive amniocentesis and CVS procedures.
The global NIPT market was valued at $534.5 million in 2016 and is estimated to reach $2,388.3 million by the end of 2022, growing with a CAGR of of 17.5% from 2016 to 2023. A whopping number of 607,000 prenatal tests were performed in 2016, which is anticipated to reach 2,386,207 tests in 2022, increasing at a CAGR of 18.8% from 2016 to 2023. As compared to invasive tests, non-invasive prenatal tests have high accuracy and the early detection ability. The global NIPT market indicates an exponential growth due to factors such as high market penetration in the untapped countries of Europe and Asia and continuously rising maternal age. The only hurdle for this market faces are the ethical and regulatory issues, related to the rate of abortions in NIPT.
The NIPTs currently available in the global market are MaterniT21 PLUS, Harmony, Panoram verifi, NIFTY, PrenaTest, BambniTest, informaSeq and VisibiliT, and others. Among these, VisibiliT (Sequenom, Inc.) is projected to be the fastest growing segment, expanding at a CAGR of 49.5% from 2016 to 2023. BIS Healthcare has compiled an extensive market research report on ‘Global Non-Invasive Prenatal Testing Market, Forecast and Analysis, 2016 & 2023’. The market analysis report provides an in-depth analysis of the key development strategies, marketing strategies and market trend dynamics which includes drivers, restraints and opportunities prevailing in the industry.
For further queries, please write to us at [email protected] or call us at: +1 650 228 0182.